Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 89.00 | |
2 mg | In stock | $ 136.00 | |
5 mg | In stock | $ 263.00 | |
10 mg | In stock | $ 422.00 | |
25 mg | In stock | $ 689.00 | |
50 mg | In stock | $ 981.00 | |
100 mg | In stock | $ 1,350.00 |
Description | IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development. |
In vitro | IAXO-102 (10 μM, for 17 hours) suppresses LPS induced pro-inflammatory proteins MCP-1 and IL-8 production in HUVEC. IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells. |
In vivo | IAXO-102 (3 mg/kg/day, s.c. for 28 days) significantly retards Angiotensin II-induced increase in aortic diameter in mice. |
Molecular Weight | 585.94 |
Formula | C35H71NO5 |
CAS No. | 1115270-63-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 45 mg/mL (76.8 mM), sonification is recommended.
DMSO: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IAXO-102 1115270-63-7 Immunology/Inflammation TLR IAXO 102 Toll-like Receptor (TLR) Inhibitor IAXO102 inhibit inhibitor